Reaction
Administration Site Extravasation reporting signals
As of the last recalculation, Administration Site Extravasation appears in 972 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is FLUOROURACIL CREAM, 0.5% (PRR 16.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Fluorouracil Cream, 0.5% | 57 | 16.9 | 17.0 |
| Fluorouracil | 57 | 16.7 | 16.7 |
| Oxaliplatin | 53 | 16.1 | 16.1 |
| Doxorubicin Hydrochloride | 24 | 16.1 | 16.1 |
| Dextrose | 9 | 14.8 | 14.8 |
| Doxorubicin | 58 | 14.8 | 14.8 |
| Remdesivir | 9 | 14.6 | 14.6 |
| Dextrose Monohydrate | 9 | 14.5 | 14.6 |
| Iron Sucrose | 6 | 13.6 | 13.6 |
| Panitumumab | 9 | 12.4 | 12.4 |
| Regorafenib | 6 | 11.1 | 11.1 |
| Pemetrexed | 11 | 11.1 | 11.1 |
| Brentuximab Vedotin | 5 | 10.5 | 10.5 |
| Granisetron | 5 | 10.3 | 10.3 |
| Carboplatin | 50 | 8.8 | 8.8 |
| Alteplase | 6 | 8.6 | 8.6 |
| Docetaxel Anhydrous | 24 | 7.8 | 7.8 |
| Docetaxel | 24 | 7.8 | 7.8 |
| Ado-Trastuzumab Emtansine | 3 | 7.6 | 7.6 |
| Pemetrexed Disodium | 13 | 7.4 | 7.4 |
| Rocuronium Bromide | 4 | 7.3 | 7.3 |
| Bendamustine Hydrochloride | 4 | 7.2 | 7.2 |
| Fam-Trastuzumab Deruxtecan-Nxki | 3 | 6.4 | 6.4 |
| Lutetium Lu 177 Vipivotide Tetraxetan | 3 | 4.9 | 4.9 |